

9/1/2020

Medicare Part D Formulary Change

The product changes noted below will be implemented on the Medicare Part D Plan:

New Added Products: **Effective 9/1/2020**

Drug	Reason	Cost sharing**	Restrictions***
FLAC OTIC (EAR) OIL 0.01 % DROPS	Formulary Addition	Tier 4	
GVOKE HYPOPEN 2-PACK 0.5 MG/0.1 ML SUBCUTANEOUS AUTO-INJECTOR	New Drug	Tier 3	
GVOKE HYPOPEN 2-PACK 1 MG/0.2 ML SUBCUTANEOUS AUTO-INJECTOR	New Drug	Tier 3	
TABRECTA 150 MG TABLET	New Drug	Tier 5	PA
TABRECTA 200 MG TABLET	New Drug	Tier 5	PA
TERIPARATIDE 20 MCG/DOSE (620 MCG/2.48 ML) SUBCUTANEOUS PEN INJECTOR	New Drug	Tier 5	PA QL
TOVET EMOLLIENT 0.05 % TOPICAL FOAM	Formulary Addition	Tier 2	QL

Future Removed Products: **Effective 9/1/2020**

Drug	Reason	Alternative*
didanosine 200 mg capsule, delayed release	Removed from Formulary	Please contact your doctor.
E.E.S. 400 MG TABLET	Removed from Formulary	Please contact your doctor.
ibuprofen-oxycodone 400 mg-5 mg tablet	Removed from Formulary	Please contact your doctor.
potassium chloride 40 meq/l in 5 % dextrose intravenous solution	Removed from Formulary	Please contact your doctor.
TROPHAMINE 6% INTRAVENOUS SOLUTION	Removed from Formulary	Please contact your doctor.

Cost Sharing Tier Changes: **There were no cost sharing tier changes this month.**

Mutual of Omaha Rx Plus: 20132

*Consult your Medical provider for changes or recommendations to your medical care and prescription therapy

**Please consult the plan benefit design for copay/coinsurance amounts

***Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist [LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy